Physician profile
George M Martin
NPI 1134147994
$1,973,209.91
in general payments reported to CMS, 2019-2025
32 companies · $104K in 2025
The $104K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217K · 2020: $206K · 2021: $484K · 2022: $734K · 2023: $114K · 2024: $113K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $122K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Consulting Fee: $78K · Travel and Lodging: $26K · Food and Beverage: $11K · Education: $53.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $122,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,583.00 |
| Consulting Fee | $78,430.00 |
| Travel and Lodging | $26,153.40 |
| Food and Beverage | $11,206.68 |
| Education | $53.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919,336.28 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $691,701.48 | 2019-2024 | Cabtreo, Targretin |
| Celgene Corporation | $64,313.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48,818.78 | 2020-2025 | Sotyktu |
| Dermavant Sciences, INC. | $45,332.45 | 2022-2024 | Tapinarof, Vtama |
| Leo Pharma INC. | $35,603.06 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $31,663.72 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $30,780.69 | 2019-2025 | |
| Incyte Corporation | $27,797.60 | 2019-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $20,567.25 | 2019-2025 | |
| Almirall LLC | $13,907.67 | 2019-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $11,946.45 | 2019-2025 | Blu-U, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $7,476.42 | 2019-2025 | Libtayo, Dupixent |
| Dusa Pharmaceuticals, INC. | $6,927.94 | 2019 | |
| Janssen Biotech, INC. | $5,883.90 | 2020-2025 | Tremfya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $2,897.89 | 2019 | |
| Genzyme Corporation | $2,145.22 | 2021-2025 | |
| Lilly USA, LLC | $1,869.54 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $1,220.07 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $533.16 | 2021-2025 | Nemluvio |
| Amgen INC. | $455.91 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $425.04 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $335.78 | 2019 | |
| Allergan, INC. | $320.00 | 2019-2020 | |
| Biofrontera INC. | $295.01 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Scientific Affairs, LLC | $195.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $129.10 | 2019-2021 | |
| Horizon Therapeutics Plc | $127.30 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $106.79 | 2024 | Dupixent |
| Bausch Health US, LLC | $45.28 | 2023 | |
| Blueprint Medicines Corporation | $29.06 | 2025 | Ayvakit |
| Merz North America, INC. | $22.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.